Change Password!
Reset Password!
Etoricoxib is a non-steroidal anti-inflammatory (NSAID) class of the drug, which is used to treat painful conditions such as arthritis, gout and dental pain after surgery.
Etoricoxib is a non-steroidal anti-inflammatory (NSAID) class of the drug, which is used to treat painful conditions such as arthritis, gout and dental pain after surgery. It eases the pain and reduces inflammation. Etoricoxib has been known to work by blocking the production of substances that cause pain and inflammation.
Pharmacological class: NSAID
Etoricoxib is also known as a cyclo-oxygenase-2 inhibitor. This is because it works to relieve pain and inflammation by blocking an enzyme in the body called cyclo-oxygenase-2 (COX-2). COX-2 is involved in the production of irritant substances in the body in response to disease and injury. By blocking the action of COX-2, etoricoxib reduces the symptoms of pain and inflammation.
For Osteoarthritis - 60 mg once a day
For Rheumatoid arthritis - 90 mg once a day
For Ankylosing spondylitis - 90 mg once a day
For the relief of gout - 120 mg once a day
Musculoskeletal pain - 60 mg once a day
The rate of absorption of etoricoxib is moderate when given orally and the extent of absorption is similar with oral and intravenous doses. Etoricoxib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 120 L in humans. Etoricoxib is eliminated following biotransformation to carboxylic acid and glucuronide metabolites that are excreted in urine and feces, with little of the drug (<1%) being eliminated unchanged in the urine. Etoricoxib is metabolized primarily by the cytochrome P450 (CYP) 3A4 isozyme.
Common (affecting between 1 in 10 to 1 in 100):
Uncommon (affecting 1 in 100 to 1 in 1000):
Very Rare (affecting less than 1 in 10,000):
In 12-week placebo and active comparator-controlled period of a randomized, double-blind study, patients were treated with etoricoxib 60 mg once daily (n = 224), naproxen 500 mg twice daily (n = 221), or placebo (n = 56). Etoricoxib 60 mg demonstrated efficacy significantly superior to placebo (p < or = 0.005) and comparable to naproxen 500 mg twice daily as assessed. Treatment effects were evident by day 2, maximal by week 2, and sustained over the entire 12 weeks. Etoricoxib was well tolerated for 12 weeks. Results showed etoricoxib have rapid and durable treatment effects in patients with OA of knee or hip and was generally well tolerated.1
In a randomized, double blind, active comparator controlled trial of 142 men and eight women aged 18 years or over with clinically diagnosed acute gout within 48 hours of onset, etoricoxib 120 mg was administered orally once daily for 8 days. Results concluded that etoricoxib 120 mg once daily provides rapid and effective treatment for acute gouty arthritis comparable to indomethacin 50 mg three times daily. Etoricoxib was generally safe and well tolerated in this study.2
Comments (0)